CSPC Innovation Pharmaceutical Co., Ltd.

CSPC Innovation Pharmaceutical Co., Ltd. faced a notable decline in stock performance, underperforming the broader market. The company has reported negative results for ten consecutive quarters, with significant drops in net profit and challenging financial metrics, including a negative return on capital employed and a high price-to-book ratio.

CSPC Innovation Pharmaceutical Co., Ltd. faced a significant decline in stock value, reflecting ongoing financial challenges. The company has reported negative net profits for ten consecutive quarters and has a concerning return on equity. Despite its large market capitalization, performance indicators highlight valuation concerns in the FMCG sector.

CSPC Innovation Pharmaceutical Co., Ltd. saw a notable decline in its stock today, contrasting with a slight increase in the China Shanghai Composite. The company has struggled with negative financial results over the past ten quarters, reflecting challenges in growth and performance metrics amid a fluctuating market.

CSPC Innovation Pharmaceutical Co., Ltd. saw a notable increase in its stock today, contrasting with a slight decline in the broader market. However, the company has struggled over the past year, with significant declines in both stock performance and profits, reflecting ongoing financial challenges.

CSPC Innovation Pharmaceutical Co., Ltd. faced a significant decline in stock value, reaching an intraday low amid ongoing financial challenges. The company has reported negative results for six consecutive quarters, with a drastic drop in net profit and negative operating cash flow, raising concerns about its recent performance compared to the broader market.

CSPC Innovation Pharmaceutical Co., Ltd. saw a notable intraday increase on March 10, 2026, contrasting with the broader market's performance. Despite recent gains, the company faces significant challenges, including a drastic decline in net profit and negative operating cash flow, indicating financial strain and underperformance over the past year.

CSPC Innovation Pharmaceutical Co., Ltd. saw a notable increase today, reaching an intraday high of CNY 31.99, contrasting with the modest rise of the China Shanghai Composite index. Despite this uptick, the company has struggled over the past year, facing significant declines in stock price and financial performance.

CSPC Innovation Pharmaceutical Co., Ltd. saw a notable increase today, reaching an intraday high amid a declining broader market. However, the company has struggled over the past year, with a significant drop in net profit and negative operating cash flow, raising concerns about its long-term growth prospects.

CSPC Innovation Pharmaceutical Co., Ltd. faced a significant stock decline on March 3, 2026, amid ongoing challenges. The company reported a net profit of CNY -3.33 million for the first half of the year, with a return on equity of -15.39%, indicating financial difficulties in the fast-moving consumer goods sector.

CSPC Innovation Pharmaceutical Co., Ltd. faced notable volatility on October 24, 2025, with a significant stock decline. Over the past week and month, the stock has dropped considerably, while the company has reported negative results for six consecutive quarters, raising concerns about its long-term growth metrics and profitability.

CSPC Innovation Pharmaceutical Co., Ltd. saw a notable stock decline, contrasting with the broader market's gains. The company has faced ongoing financial challenges, including significant drops in net sales and profits over recent quarters, raising concerns about its stability despite a strong year-to-date performance.

CSPC Innovation Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the minor decrease in the China Shanghai Composite. The company has faced a notable downturn over the past week and month, with ongoing financial challenges reflected in negative sales and profit metrics.

CSPC Innovation Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the Shanghai Composite's modest gain. The company has faced a notable downturn over the past week and month, despite impressive annual growth. However, it has reported negative results for six consecutive quarters, raising concerns about its financial stability.

CSPC Innovation Pharmaceutical Co., Ltd. experienced notable stock volatility on September 26, 2025, with a significant decline for the day. Despite a strong annual return, the company has faced ongoing challenges, including negative results over the last six quarters and a decline in key financial metrics. Its market capitalization is CNY 62,266 million.